Blog

Lifecycle Marketing for Biotech & Pharma Companies

by Jason Shafton

Most lifecycle programs in biotech and pharma are built once at launch and never revisited, so they miss the stages that actually move a patient toward adherence or an HCP toward a first script. We design multi-touch nurture journeys mapped to your real diagnosis-to-refill and awareness-to-prescribing timelines, sequenced so content clears Medical, Legal, and Regulatory review instead of dying there.

The Problem

HCP Nurture Stops at Awareness

Most teams build one email series for HCPs and treat it as the whole program. A specialist still evaluating first-line options gets the same message as one already prescribing a competitor's product. Without content mapped to each prescribing stage – awareness, evaluation, first prescription, dosing confidence, refill reinforcement – the sequence goes flat after the initial push and does nothing to move a hesitant prescriber forward.

Disease Education Content Dies in MLR

Marketing builds a twelve-touch education series, submits it to Medical, Legal, and Regulatory review a few weeks before launch, and half the claims get cut. The campaign ships late, thin, and disjointed because the content architecture was never built with review constraints in mind. MLR becomes a bottleneck that guts the program instead of a checkpoint that shapes it from the start.

Branded and Unbranded Messaging Collide

Unbranded disease-state content and branded prescribing content run through the same channels with no clear handoff logic. Patients and HCPs get mixed signals, unbranded assets drift toward referencing the product, and legal flags force a rebuild mid-flight. These need to run as two separate tracks with their own calendars, their own triggers, and a defined moment where one exchanges the baton for the other.

Campaigns Run on Marketing's Calendar, Not the Regulatory One

A label expansion or a new indication approval changes who the audience is and what claims are eligible overnight, but most lifecycle programs were built for the original indication and never updated. Content queued for a scheduled push sits idle while Regulatory finalizes an approval date nobody flagged to marketing. The gap between approval and a lifecycle program that reflects it often runs six to twelve months.

How We Help

We start with an assessment, not a content calendar. We map every stage of the actual journey for your therapeutic area: for patients, diagnosis, treatment decision, initiation, adherence, and refill or persistence; for HCPs, awareness, evaluation, first prescription, dosing confidence, and refill reinforcement. We audit existing content against each stage. Most companies have strong launch-day materials and almost nothing built for month three through month twelve, which is exactly where scripts get lost and patients drop off treatment.

From that map we build a lifecycle architecture with two parallel tracks – branded and unbranded – each with its own content calendar, its own trigger logic, and a documented handoff point where the two connect. Nothing runs in the same channel at the same time without a defined reason. Every stage gets an objective, a format, and a trigger: time-based for adherence check-ins, behavior-based for site visits or sample requests, or event-based for a label update or new indication.

HCP nurture gets built around actual prescribing psychology, not generic newsletters. Early-stage content addresses mechanism and differentiation for HCPs still evaluating. Mid-stage content addresses dosing, administration, and patient selection for HCPs who have prescribed once but haven't made it routine. Late-stage content reinforces continuation and handles the objections that show up after the first few patients. Each stage has its own message, its own channel mix, and its own success metric – not one KPI applied across the whole funnel.

We sequence production around MLR review from day one instead of treating it as a final gate. Architecture-level claims and platform messaging go through early review checkpoints, so individual touches move through faster review cycles later instead of triggering a full re-review each time. This is the single biggest reason lifecycle programs in this category ship late or get gutted mid-campaign, and it's fixable with sequencing, not with rushing legal.

On the patient side, we build disease-state education that respects where someone actually is: content for someone processing a new diagnosis reads differently than content for someone six months into treatment deciding whether to keep refilling. We write and structure both tracks so unbranded stays genuinely unbranded and branded content picks up cleanly once a patient or caregiver has moved past general disease understanding.

When a label expansion or new indication approval is on the calendar, we build the lifecycle program in parallel with the regulatory timeline instead of waiting for approval to start. That means content is staged and ready to route to the newly eligible audience within days of approval, not months.

Winston Francois runs this as a marketing strategy and execution function, not a CRM implementation. We are not selling you new lifecycle software or a platform migration. We build the journey maps, the content architecture, the sequencing logic, and the campaigns that run inside whatever CRM or marketing automation stack you already have.

What we deliver

A lifecycle program that treats a first-time prescriber and a lapsed one the same way isn't a lifecycle program – it's one email pretending to be six.

Our Methodology

We run lifecycle marketing engagements as 90-day sprints. Days 1 through 30 are assessment and architecture: mapping the HCP and patient journeys specific to your therapeutic area, auditing existing content against each stage, and building the branded/unbranded track structure with MLR review checkpoints designed in from the start rather than bolted on at the end.

Days 31 through 60 are build: writing and producing the content for each journey stage, setting up trigger logic in whatever platform you run, and moving the first batch of assets through review using the sequencing built in phase one. We prioritize the stages with the biggest existing gaps – usually mid-journey content for HCPs who prescribed once but haven't made it routine, and adherence-stage content for patients three to six months into treatment.

Days 61 through 90 are launch and calibration: campaigns go live in sequence, we track engagement against prescribing and refill behavior where data allows it, and we adjust triggers and content based on what's actually moving people between stages. If a label expansion or indication approval is on the near-term calendar, we build that campaign in parallel so it's ready to launch the moment approval lands rather than starting the clock after the fact.

The Insights You Want

Right in your inbox. We’ve done the work, and now we’re sharing it with you. Sign up to stay in the loop.

Get The Latest Updates


Enter your email address

How We Work

The first 30 days are discovery-heavy: we sit with your medical affairs, regulatory, and brand teams to understand the actual approval timeline, review process, and prescribing dynamics for your product before we write a single piece of content. This isn't a generic marketing audit – it's specific to how your MLR process works and where your product sits in its lifecycle.

You get a small, senior team: a strategist who owns the journey mapping and architecture, a content lead who owns branded and unbranded production, and a Winston Francois partner who stays accountable for the whole engagement. We don't hand this off to a rotating account team partway through.

Cadence is weekly during the build phase and biweekly once campaigns are live, with a standing review of what's moving through MLR and what's stuck. We adjust content sequencing in real time as review feedback comes in rather than waiting for a quarterly retrospective to fix a bottleneck.

If your biotech or pharma company has lifecycle content that stops working after launch week, or a label expansion coming and no plan for the campaign that should go with it, we should talk.

If your biotech & pharma company needs lifecycle marketing leadership, we should talk.

Expand your marketing team output with our experts

Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.

Frequently asked questions

How is lifecycle marketing different from what Winston Francois does under Lifecycle & CRM?

Lifecycle & CRM is about the tooling and automation infrastructure – the platform, the data flows, the technical trigger setup. Lifecycle marketing is the strategy and content layer: the journey maps, the messaging for each stage, the branded and unbranded content itself, and the campaign sequencing. We often work on both for the same client, but this engagement is about what gets said and when, not which platform sends it.

Can you build content that will actually clear MLR review on the first pass?

We can't guarantee zero revisions because that decision sits with your Medical, Legal, and Regulatory team. What we can do is build the content architecture around your review process from the start, get platform-level claims approved early, and structure individual touches so they don't each trigger a full re-review. That sequencing is usually what cuts review time, not writing more conservative copy.

How do you handle a lifecycle program when a new indication approval date keeps moving?

We build the campaign in parallel with the regulatory timeline and hold it staged rather than waiting for a confirmed date to start work. When the approval lands, whether on schedule or delayed, the content and triggers are ready to route to the newly eligible audience within days instead of starting production after the fact.

Do you work with both HCP-facing and patient-facing lifecycle content?

Yes, and we treat them as separate journey maps because the stages and triggers are different. HCP nurture moves through awareness, evaluation, first prescription, dosing confidence, and refill reinforcement. Patient journeys move through diagnosis, treatment decision, initiation, adherence, and refill or persistence. Some engagements cover both, some focus on one side depending on where the bigger gap is.

What do you need from us to start mapping the journey?

We need access to your current content library, whoever owns your MLR review process for a working session, and visibility into your regulatory timeline if a label expansion or new indication is in progress. We also want time with a few HCPs or patients if that research exists already, though we can work without it and build hypotheses to test in the first sprint.


Related Solutions

Solutions

Top Articles

Frank Growth – Episode 224 – The Bootstrapper’s Revenge with Alex Roy

Tuesday, June 16, 2026

Frank Growth – Episode 224 – The Bootstrapper’s Revenge with Alex Roy

Episode #224: Alex Roy — Bootstrapping an AI company for 12 years, no funding He founded an AI company in 2014—when AI was a punchline—bootstrapped it with zero outside capital, and landed Fortune 50 clients. For founders and growth operators figuring out how to build (and sell) AI products in a market that shifts every...
Frank Growth – Episode 242 – Why AI Slop Backfires with Nicole Cassese

Tuesday, October 20, 2026

Frank Growth – Episode 242 – Why AI Slop Backfires with Nicole Cassese

Episode #242: Nicole Cassese — Scaling brand voice without burning out the people behind it How to keep a brand voice consistent across 1,600+ assets and still protect the team writing them. For marketing leaders, creative directors, and copywriters running high-volume content with AI in the workflow. Nicole Cassese is the associate creative director owning...
Frank Growth – Episode 241 – What AI Still Can’t Do with Will Sartorius

Tuesday, October 13, 2026

Frank Growth – Episode 241 – What AI Still Can’t Do with Will Sartorius

Episode #241: Will Sartorius – AI didn’t kill the creative job, it moved it How to split ad creative work between AI and people so your ads stop sounding like everyone else’s. For founders and marketers running paid social who launch plenty of ads but learn little from them. Will Sartorius, CEO of Selfmade, took...
Frank Growth – Episode 246 – Google Analytics for Real Stores with Angie Westbrock

Tuesday, November 17, 2026

Frank Growth – Episode 246 – Google Analytics for Real Stores with Angie Westbrock

Episode #246: Angie Westbrock — Why Standard AI took down every autonomous checkout site How Standard AI turned an autonomous checkout company into a retail analytics business using the same tech stack. For founders and operators whose original business model isn’t working, and for anyone selling into physical retail. Angie Westbrock is CEO of Standard...

See more

Browse Categories

See more

Ready to unlock your growth?

Book Free Call

We take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.